期刊文献+

HPLC法测定达克替尼含量及有关物质 被引量:1

Determination of dacomitinib and related substances by HPLC
原文传递
导出
摘要 目的:建立测定达克替尼含量及有关物质的高效液相色谱法(high performance liquid chromatography,HPLC),以控制达克替尼的质量标准。方法:采用Agilent Eclipse XDB×C18柱(250 mm×4.6 mm,5μm);流动相为乙酸铵水溶液(30 mmol·L-1)-甲醇(20∶80);流速:1.0 mL·min-1;柱温为25℃;检测波长为252 nm;进样体积为20μL。结果:本方法能较好地分离达克替尼和杂质峰,达克替尼浓度在48.40~242.0μg·mL-1浓度范围内,线性关系良好(r=0.999 9);精密度、稳定性、重复性的RSD均<1%;回收率为99.79%,RSD=0.39%(n=9)。结论:该操作方法简便、快捷、重复性好,可用于达克替尼的含量测定。 Objective: To establish a high performance liquid chromatography(HPLC) method for the determination of dacomitinib and related substances for the purpose of quality control of dacomitinib. Methods: The determination was performed on the Agilent Eclipse XDB×C18 column(250 mm×4.6 mm,5 μm) with the mobile phase consisted of ammonium acetate solution(30 mmol·L-1)-methanol(20∶80) at a flow rate of 1.0 mL·min-1. The column temperature was set at 25 ℃, the detection wave length was set at 252 nm, and the injection size was at 20 μL. Results: The calibration curve of dacomitinib was linear in the range of 48.40~242.0 μg·mL-1(r=0.999 9) with RSDs of precision, stability, and reproducibility lower than 1% and the average recovery of dacomitinib of 99.79%,RSD=0.39%(n=9). Conclusion: This method is simple, rapid and reproducible, and can be applied for the content determination of dacomitinib and related substances.
作者 阮文静 柯尊军 杨博 赵玲 RUAN Wen-jing;KE Zun-jun;YANG Bo;ZHAO Ling(School of Biology and Pharmaceutical Engineering,Wuhan Polytechnic University,Wuhan 430023,China;Wuhan Ying Purui Pharmaceutical Technology Co.,Ltd.,Wuhan 430014,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2020年第7期822-825,共4页 Chinese Journal of New Drugs
关键词 高效液相色谱法 达克替尼 含量测定 有关物质 HPLC dacomitinib content determination related substances
  • 相关文献

参考文献2

二级参考文献24

  • 1Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second- generation irreversible pan-erbB receptor tyrosine kinase inhibitor [J]. Mol Cancer Ther, 2008, 7 (7) : 1880-1889.
  • 2Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J]. Cancer Res, 2007, 67 (24):11924-11932.
  • 3Fakhoury SA, Lee HT, Reed JE, et al. Preparation of N-(4- phenylamino-quinazolin-6-yl) amides for treating proliferative diseases: US, 20050250761 [P]. 2005-11-10. (CA 2005, 143: 460178).
  • 4Bridges A J, Zhou H, Cody DR, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of4-(3-bromoanilino)-6,7- dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J]. J Med Chem, 1996, 39(1): 267-276.
  • 5Himmelsbach F, Langkopf E, Jung B, et al. 4-Amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases: US, 6972288 [P]. 2005-12-06. (CA 2000, 133: 207919).
  • 6Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase[ J ]. Science, 1994,265(5 175):1 093 -1 095.
  • 7Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804,an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [ J ]. Cancer Res,2007,67 ( 24 ) : 11 924 - 11 932.
  • 8Ercan D, Zejnullahu K, Yonesaka K,et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor[ J ]. Oncogene,2010,29 ( 16 ) :2 346 - 2 356.
  • 9Rewcastle GW, Denny W A, Bridges AJ, et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4- [ ( phenylmethyl ) amino ] -and 4- (phenylamino) quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor [ J ]. J Med Chem, 1995,38 ( 18 ) :3 482 - 3 487.
  • 10Kalous O,Conklin D,Desai AJ,et al. Dacomitinib (PF4)0299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2- amplified breast cancer cell lines resistant to trastuzumab and lapatinib[ J]. Mol Cancer Ther,2012,11(9) :1 978 - 1 987.

共引文献4

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部